Natera: Published study highlights utility of Signatera test

Natera announced the publication of a new study in JCO Precision Oncology highlighting the clinical utility of its personalized and tumor-informed molecular residual disease test, Signatera, for postoperative risk stratification and prediction of recurrence in patients with stage I-III esophageal and gastric cancers. Key takeaways from the study include: Pre-treatment: ctDNA was detectable in 96% (23/24) of patients with preoperative samples. Post surgery: ctDNA was detected post-surgically in 23.5% of patients. ctDNA-positive patients experienced a higher rate of recurrence in comparison to ctDNA-negative patients. ctDNA-positive patients experienced inferior RFS. Surveillance setting: the recurrence rate in patients with a ctDNA-positive result was 95.2% compared to 7.9% in patients who remained ctDNA-negative. ctDNA-positive patients experienced inferior RFS. Multivariate analysis: ctDNA was the strongest prognostic factor compared to all other clinicopathological risk factors including disease stage, location, and MSI status. "This study shows how longitudinal assessment using Signatera allows for accurate post operative risk stratification and adjuvant therapy or surveillance monitoring in patients with esophagogastric cancers in a real-world setting," said Samuel Klempner, M.D., associate professor at Massachusetts General Hospital and corresponding author of the study. "Unfortunately, many gastroesophageal cancers recur after definitive treatment, and patients with advanced disease have a poor prognosis. This study highlights the potential for Signatera to better identify patients at highest risk of recurrence and help develop novel treatment approaches."